Co-morbidity in lung cancer- important but neglected: a review of the current literature

D Grose, G Devereux, R Milroy

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction
Treatment and survival rates for patients with lung cancer in Scotland appear lower than in many other European countries. Five-year survival is quoted at 6% to 7% compared with 8% to 15% in other European countries and America. There also appear to be variations in treatment rates within Scotland. Although this variation in treatment and survival is popularly interpreted as evidence of variation in facilities, access to care, and clinical practice, it is possible that the increased comorbidity and poor performance status of the Scottish population may contribute to the observed disparities in treatment and outcomes, although this has never been proven. The demonstration that comorbidity influences treatment and survival rates will have important implications for the targeting of health services resources, screening, interpretation of cancer statistics, and the assessment and management of patients with lung cancer.

Methods
In this article we have reviewed the tools currently available for assessing comorbidity and in addition have identified published works which study the effect of comorbidity in lung cancer.

Conclusion
There is no currently validated measurement tool applicable specifically to lung cancer and thus there remains a significant need for further work in this important area.

Statement of Search Strategies Used and Sources of Information
Literature searches were undertaken via PubMed and Google Scholar using various arrays of the following keywords: cancer, comorbidity, lung lancer, performance status, survival, and tools. The search was limited to articles published in peer-review journals with English as the language.
Original languageEnglish
Pages (from-to)207-211
Number of pages5
JournalLung Cancer
Volume12
Issue number4
Early online date20 Jun 2011
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Comorbidity
Lung Neoplasms
Morbidity
Scotland
Survival
Survival Rate
Architectural Accessibility
Peer Review
Health Resources
Early Detection of Cancer
PubMed
Health Services
Language
Therapeutics
Population

Keywords

  • clinical epidemiology
  • lung cancer

Cite this

Co-morbidity in lung cancer- important but neglected : a review of the current literature. / Grose, D; Devereux, G; Milroy, R.

In: Lung Cancer, Vol. 12, No. 4, 07.2011, p. 207-211.

Research output: Contribution to journalArticle

@article{cc3e039441214846944621b14655134e,
title = "Co-morbidity in lung cancer- important but neglected: a review of the current literature",
abstract = "IntroductionTreatment and survival rates for patients with lung cancer in Scotland appear lower than in many other European countries. Five-year survival is quoted at 6{\%} to 7{\%} compared with 8{\%} to 15{\%} in other European countries and America. There also appear to be variations in treatment rates within Scotland. Although this variation in treatment and survival is popularly interpreted as evidence of variation in facilities, access to care, and clinical practice, it is possible that the increased comorbidity and poor performance status of the Scottish population may contribute to the observed disparities in treatment and outcomes, although this has never been proven. The demonstration that comorbidity influences treatment and survival rates will have important implications for the targeting of health services resources, screening, interpretation of cancer statistics, and the assessment and management of patients with lung cancer.MethodsIn this article we have reviewed the tools currently available for assessing comorbidity and in addition have identified published works which study the effect of comorbidity in lung cancer.ConclusionThere is no currently validated measurement tool applicable specifically to lung cancer and thus there remains a significant need for further work in this important area.Statement of Search Strategies Used and Sources of InformationLiterature searches were undertaken via PubMed and Google Scholar using various arrays of the following keywords: cancer, comorbidity, lung lancer, performance status, survival, and tools. The search was limited to articles published in peer-review journals with English as the language.",
keywords = "clinical epidemiology, lung cancer",
author = "D Grose and G Devereux and R Milroy",
year = "2011",
month = "7",
doi = "10.1016/j.cllc.2011.03.020",
language = "English",
volume = "12",
pages = "207--211",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - Co-morbidity in lung cancer- important but neglected

T2 - a review of the current literature

AU - Grose, D

AU - Devereux, G

AU - Milroy, R

PY - 2011/7

Y1 - 2011/7

N2 - IntroductionTreatment and survival rates for patients with lung cancer in Scotland appear lower than in many other European countries. Five-year survival is quoted at 6% to 7% compared with 8% to 15% in other European countries and America. There also appear to be variations in treatment rates within Scotland. Although this variation in treatment and survival is popularly interpreted as evidence of variation in facilities, access to care, and clinical practice, it is possible that the increased comorbidity and poor performance status of the Scottish population may contribute to the observed disparities in treatment and outcomes, although this has never been proven. The demonstration that comorbidity influences treatment and survival rates will have important implications for the targeting of health services resources, screening, interpretation of cancer statistics, and the assessment and management of patients with lung cancer.MethodsIn this article we have reviewed the tools currently available for assessing comorbidity and in addition have identified published works which study the effect of comorbidity in lung cancer.ConclusionThere is no currently validated measurement tool applicable specifically to lung cancer and thus there remains a significant need for further work in this important area.Statement of Search Strategies Used and Sources of InformationLiterature searches were undertaken via PubMed and Google Scholar using various arrays of the following keywords: cancer, comorbidity, lung lancer, performance status, survival, and tools. The search was limited to articles published in peer-review journals with English as the language.

AB - IntroductionTreatment and survival rates for patients with lung cancer in Scotland appear lower than in many other European countries. Five-year survival is quoted at 6% to 7% compared with 8% to 15% in other European countries and America. There also appear to be variations in treatment rates within Scotland. Although this variation in treatment and survival is popularly interpreted as evidence of variation in facilities, access to care, and clinical practice, it is possible that the increased comorbidity and poor performance status of the Scottish population may contribute to the observed disparities in treatment and outcomes, although this has never been proven. The demonstration that comorbidity influences treatment and survival rates will have important implications for the targeting of health services resources, screening, interpretation of cancer statistics, and the assessment and management of patients with lung cancer.MethodsIn this article we have reviewed the tools currently available for assessing comorbidity and in addition have identified published works which study the effect of comorbidity in lung cancer.ConclusionThere is no currently validated measurement tool applicable specifically to lung cancer and thus there remains a significant need for further work in this important area.Statement of Search Strategies Used and Sources of InformationLiterature searches were undertaken via PubMed and Google Scholar using various arrays of the following keywords: cancer, comorbidity, lung lancer, performance status, survival, and tools. The search was limited to articles published in peer-review journals with English as the language.

KW - clinical epidemiology

KW - lung cancer

U2 - 10.1016/j.cllc.2011.03.020

DO - 10.1016/j.cllc.2011.03.020

M3 - Article

VL - 12

SP - 207

EP - 211

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 4

ER -